

Reading way ↑



1085520

THERAPEUTIC INDICATIONS

Please refer to package insert for further information.
In all cases, you must strictly comply with your doctor's prescription.

SHELF LIFE

Do not exceed the expiry date indicated on the pack.


DOSAGE AND METHOD OF ADMINISTRATION

Strictly comply with your doctor's prescription.
The solution for injection in a pre-filled syringe is ready for use.

For immediate and single use following first opening.
This product is for deep subcutaneous injection.
Please refer to package insert for further information and recommended dosage.

**CONTRAINDICATIONS / ADVERSE EFFECTS /
DRUG INTERACTIONS / WARNINGS**

Please refer to package insert for further information



Batch No. : xxxxxx
Mfg. Date : MM/YYYY
Exp. Date : MM/YYYY
(มส.มส.)

KEEP OUT OF REACH OF CHILDREN
(JAUHKAN UBAT DARIPADA KANAK KANAK)
Ubat Terkawal

Imported into Malaysia by:
ZUELLIG PHARMA SDN BHD (4013-D),
No. 15 Persiaran Pasak Bumi, Seksyen U8,
Perindustrian Bukit Jelutong,
45150 Shah Alam, Selangor, Malaysia

Imported into Thailand by:
Zuellig Pharma Limited, Bangkok

MAL12085051AZ
SIN14289P
Reg.No.: 1C 31/61 (NC)



3 582186 000939

120 mg

Somatuline® Autogel® 120 mg
lanreotide acetate

Prolonged Release Solution for injection in a pre-filled syringe

PRESENTATION AND FORM

Somatuline Autogel 120 mg, prolonged release solution for injection.
Box containing one 0.5 ml pre-filled syringe with an automated safety system.



COMPOSITION PER UNIT DOSE

Each pre-filled syringe contained:
Active substance:
Lanreotide (I.N.N),
presented as acetate 120 mg
Excipient: Water for injections.
Glacial acetic acid (for pH adjustment)



Store in a refrigerator between + 2 °C and + 8 °C.
Store in original package in order to protect from light.

Use as directed by doctor

℞ Prescription item only



Somatuline® Autogel® 120 mg
lanreotide acetate

Prolonged Release Solution for injection in a pre-filled syringe



ยาอันตราย

**New device with safety features.
Read instructions before use.**

120 mg

Somatuline® Autogel® 120 mg

lanreotide acetate
Prolonged Release Solution
for injection in a pre-filled syringe

120 mg

Prolonged Release Formulation

120 mg

Somatuline® Autogel® 120 mg

lanreotide acetate
Prolonged Release Solution
for injection in a pre-filled syringe



French Marketing Authorisation Holder:
IPSEN PHARMA SAS, FRANCE

Name and address of manufacturer:
IPSEN PHARMA BIOTECH
Chemin Departamental No. 402-83870 Signes-France

	Customer	Ipsen			Colours Used	Fonts Used	Notes
	SAP Code	1085520			Black	Helvetica Neue LT Com 9pt	
	SAP Description	CTN SOMATULINE AUTOGEL 120MG 3.0 MYSGTH			Keyline (Non-Printing)	Helvetica Neue (code) 7pt	
	Proof / Iteration	3			PANTONE 803 C	Times New Roman 7.6pt	
	Artwork Type	Carton			PANTONE Red 032 C	OCR B Std 10pt	
	Profile Ref	N/A			PANTONE Violet C		
	Size	107 x 25 x 296 mm			Reactive Ink		
	Specification Ref	N/A			Technical Info (Non-Printing)		
	Barcode Type	EAN 13	Reel Direction	N/A	Varnish Free (Non-Printing)		
	Pharmacode	706	Copy Position	N/A	Cirrus_Info_Box		
Approval Signature							
Date							
Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.							
	Proof By	KJA	Date	14/05/2025			

Username	Full Name	Status	Date/Time (UTC)
noc79254	Noemie Cruvellier	Approved	16-May-2025 01:10:48
boc68879	Bongkoch CHAROENSUPKUL	Approved	19-May-2025 04:50:58
pab99462	Pascal Brunel	Approved	19-May-2025 08:59:29